• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study.

作者信息

Michelis F V, Atenafu E G, Couban S, Frazer J, Shivakumar S, Hogge D E, Toze C L, Rajkhan W, Kim H J, Daly A, Slaby J, Finke J, Kiss T, Bredeson C, Sabloff M, Sheppard D, Bakkar M, Brune M, Wall D A, Paulson K, Popradi G, Walker I, Messner H A

机构信息

Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

出版信息

Bone Marrow Transplant. 2016 Jul;51(7):1019-21. doi: 10.1038/bmt.2016.60. Epub 2016 Mar 14.

DOI:10.1038/bmt.2016.60
PMID:26974273
Abstract
摘要

相似文献

1
Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study.首次缓解持续时间和造血细胞移植特异性合并症指数而非年龄可预测处于第二次完全缓解期接受移植的急性髓系白血病患者的生存情况：一项回顾性多中心研究
Bone Marrow Transplant. 2016 Jul;51(7):1019-21. doi: 10.1038/bmt.2016.60. Epub 2016 Mar 14.
2
Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR.首次缓解持续时间、造血细胞移植特异性合并症指数和患者年龄可预测急性髓系白血病患者第二次完全缓解期移植后的生存率。
Bone Marrow Transplant. 2013 Nov;48(11):1450-5. doi: 10.1038/bmt.2013.71. Epub 2013 May 20.
3
Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.患者年龄、缓解状态以及综合评分中的造血细胞移植特异性合并症指数（HCT-CI）对处于首次完全缓解（CR1）和第二次完全缓解（CR2）期接受异基因造血细胞移植的急性髓系白血病（AML）患者具有预后价值。
Bone Marrow Transplant. 2015 Nov;50(11):1405-10. doi: 10.1038/bmt.2015.165. Epub 2015 Jul 13.
4
Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.对于年龄≥60 岁的急性髓细胞白血病患者，同种异体移植的获益仅限于在移植时处于完全缓解 1 期的患者。
Biol Blood Marrow Transplant. 2014 Apr;20(4):474-9. doi: 10.1016/j.bbmt.2013.12.560. Epub 2013 Dec 15.
5
Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.基于静脉注射白消安或全身照射的清髓性预处理方案对急性髓系白血病缓解期并接受异基因造血细胞移植的儿科患者的结局比较：来自日本造血细胞移植学会的报告
Biol Blood Marrow Transplant. 2015 Dec;21(12):2141-2147. doi: 10.1016/j.bbmt.2015.08.011. Epub 2015 Aug 10.
6
Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.单倍体核型作为首次完全缓解期接受异基因造血干细胞移植治疗的急性髓系白血病患者的不良预后因素：代表欧洲血液与骨髓移植协会急性白血病工作组进行的一项回顾性调查
Haematologica. 2016 Feb;101(2):248-55. doi: 10.3324/haematol.2015.132654. Epub 2015 Nov 20.
7
Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database.未处理的单倍体相合与匹配的非亲缘供者异基因干细胞移植用于首次缓解期的成年急性髓系白血病患者：一项将北京方案与欧洲血液与骨髓移植协会（EBMT）数据库进行配对匹配的回顾性比较研究
Haematologica. 2016 Aug;101(8):e352-4. doi: 10.3324/haematol.2015.140509. Epub 2016 Apr 14.
8
Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.基于苏消安预处理方案治疗急性髓系白血病患者的长期预后：欧洲血液与骨髓移植学会急性白血病工作组的报告
Cancer. 2017 Jul 15;123(14):2671-2679. doi: 10.1002/cncr.30646. Epub 2017 Mar 22.
9
Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens.首次完全缓解的急性髓系白血病患者接受减低强度预处理异基因造血干细胞移植后的结局：两种方案的比较
Bone Marrow Transplant. 2008 Nov;42(10):689-91. doi: 10.1038/bmt.2008.231. Epub 2008 Aug 4.
10
Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.急性白血病同基因造血干细胞移植的结果：首次完全缓解期接受移植的成人患者预后的危险因素
Haematologica. 2008 Jun;93(6):834-41. doi: 10.3324/haematol.11277. Epub 2008 May 10.

引用本文的文献

1
Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.缺乏证据支持移植前巩固治疗对接受异基因造血干细胞移植的急性髓系白血病完全缓解2期患者有显著益处。
Cancers (Basel). 2025 Apr 19;17(8):1364. doi: 10.3390/cancers17081364.
2
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission.在首次缓解期和第二次缓解期接受异基因干细胞移植的 AML 患者中，MRD 状态的影响。
Blood Adv. 2022 Aug 9;6(15):4570-4580. doi: 10.1182/bloodadvances.2022007168.
3

本文引用的文献

1
Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR.首次缓解持续时间、造血细胞移植特异性合并症指数和患者年龄可预测急性髓系白血病患者第二次完全缓解期移植后的生存率。
Bone Marrow Transplant. 2013 Nov;48(11):1450-5. doi: 10.1038/bmt.2013.71. Epub 2013 May 20.
2
Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission.未在首次缓解期进行移植的急性髓系白血病患者的治愈率。
J Clin Oncol. 2013 Apr 1;31(10):1293-301. doi: 10.1200/JCO.2011.40.5977. Epub 2013 Feb 25.
3
Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia.
复发性急性髓系白血病异基因干细胞移植预后的预测特征
Curr Oncol. 2017 Apr;24(2):e123-e130. doi: 10.3747/co.24.3485. Epub 2017 Apr 27.
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.
初发缓解后成人急性髓系白血病患者的预后因素和结局。
Haematologica. 2010 Nov;95(11):1857-64. doi: 10.3324/haematol.2010.027516. Epub 2010 Jul 15.
4
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.量化异基因造血干细胞移植对复发急性髓系白血病的生存获益。
Biol Blood Marrow Transplant. 2009 Nov;15(11):1431-8. doi: 10.1016/j.bbmt.2009.07.008. Epub 2009 Sep 1.
5
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.细胞遗传学对首次或第二次完全缓解的急性髓系白血病患者单倍体相合无关供者造血干细胞移植结局的影响
Blood. 2007 Jul 1;110(1):409-17. doi: 10.1182/blood-2006-10-043299. Epub 2007 Mar 20.
6
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.造血细胞移植（HCT）特异性合并症指数：一种用于异基因造血细胞移植前风险评估的新工具。
Blood. 2005 Oct 15;106(8):2912-9. doi: 10.1182/blood-2005-05-2004. Epub 2005 Jun 30.
7
Prognostic index for adult patients with acute myeloid leukemia in first relapse.初治复发的成年急性髓系白血病患者的预后指数
J Clin Oncol. 2005 Mar 20;23(9):1969-78. doi: 10.1200/JCO.2005.06.027. Epub 2005 Jan 4.
8
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).
Bone Marrow Transplant. 2000 Dec;26(11):1157-63. doi: 10.1038/sj.bmt.1702690.
9
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.诊断细胞遗传学对急性髓系白血病预后的重要性：对参加医学研究委员会AML 10试验的1612例患者的分析。医学研究委员会成人及儿童白血病工作组。
Blood. 1998 Oct 1;92(7):2322-33.